FcαRI (CD89) as a novel trigger molecule for bispecific antibody therapy

Blood

Volumn 90, Issue 11, 1997, Pages 4485-4492

  Valerius, Thomas ^a   Stockmeyer, Bernhard ^b   Van Spriel, Annemiek B ^b   Graziano, Robert F ^b   Van Den Herik Oudijk, Ingrid E ^b   Repp, Roland ^b   Deo, Yashwant M ^b   Lund, John ^b   Kalden, Joachim R ^b   Gramatzki, Martin ^b   Van De Winkel, Jan G J ^b  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FC RECEPTOR; MONOCLONAL ANTIBODY; BISPECIFIC ANTIBODY; FC(ALPHA) RECEPTOR; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN A; LEUKOCYTE ANTIGEN;

ALTERNATIVE RNA SPLICING; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY SPECIFICITY; ARTICLE; CANDIDA ALBICANS; CELL KILLING; CELL PROLIFERATION; CHROMOSOMAL LOCALIZATION; CYTOLYSIS; EFFECTOR CELL; HUMAN; HUMAN CELL; IMMUNOTHERAPY; PHAGOCYTOSIS; PRIORITY JOURNAL; TARGET CELL; DRUG COMBINATION; DRUG POTENTIATION; IMMUNOLOGY; METHODOLOGY; NEUTROPHIL; PASSIVE IMMUNIZATION;

ANTIBODIES, BISPECIFIC; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD; CANDIDA ALBICANS; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOGLOBULIN A; NEUTROPHILS; PHAGOCYTOSIS; RECEPTORS, FC;

EID: 0030613845     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v90.11.4485     Document Type: Article

References (39)

1. Dillmah RO: Antibodies as cytotoxic therapy. J Clin Oncol 12:1497, 1994
2. Grossbard ML, Press OW, Appelbaum FR, Bernstein ID, Nadler LM: Monoclonal antibody-based therapies of leukemia and lymphoma. Blood 80:863, 1992
3. Brüggemann M, Williams GT, Bindon CI, Clark MR, Walker MR, Jefferis R, Waldmann H, Neuberger MS: Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies. J Exp Med 166:1351, 1987
4. Riechmann L, Clark M, Waldmann H, Winter G: Reshaping human antibodies for therapy. Nature 332:323, 1988
5. HER2 monoclonal antibody in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neu. J Clin Oncol 14:737, 1996
6. McLaughlin P, Grillo-Lopez AJ, Czuczman M, Link BK, Levy R, Dillman RO, Ho A, Bennett JM, Heyman MR, Schilder RJ, Cabanillas F, Rogers J, Dallaire BK: Preliminary report on a phase III pivotal trial of the anti-CD20 antibody IDEC-C2B8 in patients with relapsed low-grade or follicular lymphoma. Proc Am Sci Clin Oncol 15:417, 1996 (abstr)
7. Lichtenstein A: Granulocytes as possible effectors of tumor immunity, in Oettgen HF (ed): Human Cancer Immunology I. Philadelphia, PA, Saunders, 1990, p 731
8. Musiani P, Modesti A, Giovarelli M, Cavallo F, Colombo MP, Lollini PL, Forni G: Cytokines, tumour-cell death and immunogenicity: A question of choice. Immunol Today 18:32, 1997
9. Elsässer D, Valerius T, Repp R, Weiner GJ, Deo Y, Kalden JR, Van de Winkel JGJ, Stevenson GT, Glennie MJ, Gramatzki M: HLA class II as potential target antigen on malignant B cells for therapy with bispecific antibodies in combination with G-CSF. Blood 87:3803, 1996
10. Stockmeyer B, Valerius T, Repp R, Heijnen IAFM, Bühring HJ, Deo YM, Kalden JR, Gramatzki M, Van de Winkel JGJ: Preclinical studies with FcγR bispecific antibodies and G-CSF primed neutrophils as effector cells against HER-2/neu overexpressing breast cancer. Cancer Res 57:696, 1997
11. Ravetch JV, Kinet JP: Fc receptors. Ann Rev Immunol 9:457, 1991
12. Van de Winkel JGJ, Capel PJA: Human IgG Fc receptor heterogeneity: Molecular aspects and clinical implications. Immunol Today 14:215, 1993
13. Pleass RJ, Andrews PD, Kerr MA, Woof JM: Alternative splicing of the human IgA Fc receptor CD89 in neutrophils and eosinophils. Biochem J 318:771, 1996
14. van Dijk TB, Bracke M, Caldenhoven E, Raaijmakers JAM, Lammers JWJ, Koenderman L, de Groot RP: Cloning and charcterization of FcαRb, a novel Fcα receptor (CD89) isoform expressed in eosinophils and neutrophils. Blood 88:4229, 1996
15. Morton HC, Schiel AE, Janssen SWJ, Van de Winkel JGJ: Alternatively spliced forms of the human myeloid Fcα receptor (CD89) in neutrophils. Immunogenetics 43:246, 1996
16. Shen L: Receptors for IgA on phagocytic cells. Immunol Res 11:273, 1992
17. Morton HC, van Egmond M, Van de Winkel JGJ: Structure and function of human IgA Fc receptors (FcαR). Crit Rev Immunol 16:423, 1996
18. Weisbart RH, Kacena A, Schuh A, Golde DW: GM-CSF induces human neutrophil IgA-mediated phagocytosis by an IgA Fc receptor activation mechanism. Nature 332:647, 1988
19. Morton HC, van den Herik-Oudijk IE, Vossebeld P, Snijders A, Verhoeven AJ, Capel PJA, Van de Winkel JGJ: Functional association between the human myeloid IgA Fc receptor (CD89) and the EcR γ chain. Molecular basis for CD89/FcR γ chain association. J Biol Chem 270:29781, 1995
20. Guyre PM, Graziano RF, Vance BA, Morganelli PM, Fanger MW: Monoclonal antibodies that bind to distinct epitopes on FcγRI are able to trigger receptor function. J Immunol 143:1650, 1989
21. Fanger MW, Morganelli PM, Guyre PM: Bispecific antibodies. Crit Rev Immunol 12:101, 1992
22. Deo YM, Graziano RF, Repp R, Van de Winkel JGJ: Clinical significance of IgG receptors and FcγR-directed immunotherapies. Immunol Today 18:127, 1997
23. Pizzo PA: Granulocytopenia and cancer therapy: Past problems, current solutions, future challenges. Cancer 54:2649, 1984
24. Schaffner A, Davis CE, Schaffner T, Markert M, Douglas H, Braude AI: In vitro susceptibility of fungi to killing by neutrophil granulocytes discriminates between primary pathogenicity and opportunism. J Clin Invest 78:511, 1986
25. Lund J, Takahashi N, Pound JD, Goodall M, Jefferis R: Multiple interactions of IgG with its core oligosaccharide can modulate recognition by complement and human Fcγ receptor I and influence the synthesis of its oligosaccharide chains. J Immunol 157:4963, 1996
26. Ring DB, Kassel JA, Hsieh-Ma ST, Bjorn MJ, Tringale F, Eaton AM, Reid SA, Frankel AE, Nadji M: Distribution and physical properties of BCA200, a Mr 200,000 glycoprotein selectively associated with human breast cancer. Cancer Res 49:3070, 1989
27. Monteiro RC, Cooper MD, Kubagawa H: Molecular heterogenity of Fcα receptors detected by receptor-specific monoclonal antibodies. J Immunol 148:1764, 1992
28. Shen L, Lasser R, Fanger MW: My 43, a monoclonal antibody that reacts with human myeloid cells inhibits monocyte IgA binding and triggers function. J Immunol 143:4117, 1989
29. Looney RJ, Abraham GN, Anderson CL: Human monocytes and U937 cells bear two distinct Fc receptors for IgG. J Immunol 136:1641, 1986
30. Fleit HB, Wright SD, Unkeless JC: Human neutrophil Fcγ receptor distribution and structure. Proc Natl Acad Sci USA 79:3275, 1982
31. 3 antibody derivates, in Gallagher G, Rees RC, Reynolds CW (eds): Tumour Immunobiology, A Practical Approach. Oxford, UK, Oxford University Press, 1995, p 225
32. Marx JL: Suppressing autoimmunity in mice. Science 221:843, 1983
33. Graziano RF, Fanger MW: Human monocyte-mediated cytotoxicity: The use of Ig-bearing hybridomas as target cells to detect trigger molecules on the monocyte cell surface. J Immunol 138:945, 1987
34. Valerius T, Repp R, de Wit TPM, Berthold S, Platzer E, Kalden JR, Gramatzki M, Van de Winkel JGJ: Involvement of the high affinity receptor for IgG (FcγRI; CD64) in enhanced tumor cell cytotoxicity of neutrophils during G-CSF therapy. Blood 82:931, 1993
35. Repp R, Valerius T, Sendler A, Gramatzki M, Iro H, Kalden JR, Platzer E: Neutrophils express the high affinity receptor for IgG (Fc-gamma RI; CD64) after in vivo application of rhG-CSF. Blood 78:885, 1991
36. Heijnen IAFM, van Vugt MJ, Fanger NA, Graziano RF, de Wit TPM, Hofhuis FMA, Guyre PM, Capel PJA, Verbeek JS, Van de Winkel JGJ: Antigen targeting to myeloid-specific human FcγRI/ CD64 triggers enhanced antibody responses in transgenic mice. J Clin Invest 97:331, 1996
37. Dombrowicz D, Flamand V, Miyajima I, Ravetch JV, Galli SJ, Kinet JP: Absence of Fc∈RIα chain results in upregulation of FcγRIII-dependent mast cell degranulation and anaphylaxis; evidence of competition between Fc∈RI and FcγRIII for limiting amounts of FcR β and γ chains. J Clin Invest 99:915, 1997
38. Weber JS, Spears L, Deo Y, Link JL: Phase I study of a HER-2/neu bispecific antibody with G-CSF in patients with metastatic breast cancer. Proc Am Sci Clin Oncol 15:354, 1996 (abstr)
39. Valerius T, Repp R, Wieland G, Deo Y, Van de Winkel JGJ, Kalden JR, Lang N, Gramatzki M: Bispecific antibody MDX210 (FcγRI × HER-2/neu) in combination with G-CSF: Results of a phase I trial in patients with metastatic breast cancer. Proc Am Sci Clin Oncol 15:108, 1996 (abstr)